A, Rad50 was immunoprecipitated from EBV-transformed human ATMwt/wt or B, ATM−/− lymphoblasts. The immunoprecipates were separated by SDS-PAGE and immunoblotted for Rad50 and co-associating proteins, Mre11 and Nbs1. These same immunoprecipitates were also probed with a phospho-S/T-Q specific antibody that recognises ATM/ATR motifs (two right panels). Rad50 was phosphorylated in the wild-type cells but not in the ATM null cells in response to DNA damage as predicted. Nbs1 phosphorylation was reduced, but not eliminated, in the ATM null cells, suggesting that other PIKK kinases are also active in these lymphoblast cell lines, but that these are not responsible for Rad50 phosphorylation. When probing with the phospho-S/T-Q specific antibody, the Nbs1 band is stronger than the Rad50 band due to the presence of three ATM sites in Nbs1 but only a single site in Rad50. An unidentified protein, p140 was recognised by the phospho-S/T-Q antibody. C,D Human osteosarcoma U2OS cells were left untreated or treated with paclitaxel/doxorubicin (G2/M checkpoint arrest), paclitaxel (mitotic arrest), or paclitaxel with the CDK-inhibitor Roscovitine. Subsequently, cells were harvested and analysed in parallel by immunoblotting and FACS (C panel only for FACS). Percentages of mitotic cells (phospho-Histone H3 staining) and G2/M cells (propidium iodide) as determined by FACS analyses are shown below panel C. Immunoblotting of total cell lysates (TCL) or 53BP1 immunoprecipitations was performed with antibodies indicated to the right of the panels (see Supplemental Experimental Procedures). Only 53BP1 immunoprecipitated from mitotic cells was recognised by the phospho-specific antibody MPM-2, indicating that CDK1 is responsible for 53BP1 phosporylation in vivo.